Nov 25, 2018
The ASCO Post reported that Dr. Amar Kishan, an assistant professor of radiation oncology and a member of the UCLA Jonsson Comprehensive Cancer Center, was recognized by the Radiation Oncology Institute for his study highlighting the value of radiation therapy in the treatment of aggressive prostate cancer.
Oct 26, 2018
HealthDay News, Doctors Lounge, Drugs.com, Renal and Urology News and MPR reported on a new study that found stereotactic body radiation therapy is a safe and effective treatment for men with low- and intermediate-risk prostate cancer. Dr. Amar Kishan, assistant professor of radiation oncology and a member of the UCLA Jonsson Comprehensive Cancer Center, presented the research at the annual American Society of Radiation Oncology meeting.
Oct 22, 2018
Amar U. Kishan, MD, UCLA IUO researcher and radiation oncologist, was the lead author on recent study findings that were presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). According to a long-term, multi-institutional study, stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer. Press Release >
Oct 19, 2018
Futurity.org, in a story about the use of artificial intelligence in cancer treatment, referenced a study conducted at the UCLA Institute of Urologic Oncology about metastatic prostate cancer.
Oct 15, 2018
Dr. Amar Kishan -- Amar U. Kishan, MD, UCLA IUO researcher and radiation oncologist, has been selected by The Radiation Oncology Institute (ROI) to receive the 2018 Publication Award in recognition of the outstanding research published in the manuscript, “Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.” Press Release >
Oct 11, 2018
Owen Witte, PhD -- ScienceDaily, Technology Networks, Drug Target Review, Medical Xpress, The Global Health, Medicine News Line, Diario Rotativo and several other outlets reported on UCLA research finding a common process in the development of late-stage, small cell cancers of the prostate and lung, Dr. Owen Witte, founding director of the UCLA Broad Stem Cell Research Center, a distinguished professor of microbiology, immunology and molecular genetics and UCLA IUO researcher, and Thomas Graeber, a member of the UCLA Broad Stem Cell Research Center, director of the UCLA Metabolomics Center and professor of molecular and medical pharmacology, led the research along with first author Jung Wook Park, a post-doctoral fellow in the department of microbiology, immunology, and molecular genetics. Witte and Graeber are also members of the UCLA Jonsson Comprehensive Cancer Center.
Oct 02, 2018
Paul C. Boutros, PhD -- Medical Xpress reported on research by Paul Boutros, director of cancer data sciences at the UCLA Jonsson Comprehensive Cancer Center, which investigated sex differences in cancer genes to see if these differences could help predict responses to treatment.
Sep 28, 2018
Andrew Goldstein, an assistant professor of UCLA Molecular, Cell and Developmental Biology and Urology, as well as a faculty member of the UCLA IUO, will be honored by the American Cancer Society with its Giants of Science Hope award. Dr. Goldstein's research focuses on developing new treatments for prostate cancer. UCLA Newsroom >
Sep 22, 2018
Dr. Amar Kishan -- Medicalresearch.com reported on a new study finding that combining radiation and androgen deprivation therapy (hormonal therapy) is critical in treating men with advanced prostate cancer. The senior author, Dr. Amar Kishan, assistant professor of radiation oncology and member of the UCLA Jonsson Comprehensive Cancer Center, was cited.
Sep 20, 2018
Dr. Christopher Saigal -- Health News Digest featured Dr. Christopher Saigal, vice chair of urology, in a story about three facts patients should know about prostate cancer. Saigal is a member of the UCLA Jonsson Comprehensive Cancer Center.
Sep 20, 2018
Dr. Amar Kishan -- A Q&A with UCLA researcher and radiation oncologist Dr. Amar Kishan. Dr. Kishan, a member of the UCLA Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology, is trying to find ways to improve the optimal duration of androgen deprivation therapy when used with radiation. By using a patient’s Gleason score, he is hoping to help establish a more personalized treatment plan for each individual. UCLA JCCC Newsroom >
Sep 17, 2018
UCLA researchers develop mechanism for characterizing function of rare tumor cells
UCLA researchers, including IUO's Dr. Matthew Rettig, have created a quick and effective mechanism to measure how circulating tumor cells perform functions that drive the disease of cancer. These findings could lead to more personalized treatments for people with cancer. News release >
Aug 20, 2018
Dr. Robert Reiter -- Renal & Urology News covered UCLA research finding a decline in the use of radical prostatectomy to treat prostate cancer. The study was led by Dr. Robert Reiter, a professor and Bing Chair in Urologic Oncology in the department of urology at the David Geffen School of Medicine at UCLA and co-director of the Genitourinary Oncology Program Area at the UCLA Jonsson Comprehensive Cancer Center.
Aug 10, 2018
Dr. Mark Litwin - The Los Angeles Business Journal reported on a three-year grant to Dr. Mark Litwin, a professor in urology and a member of the UCLA Jonsson Comprehensive Cancer Center. The grant supports the department’s efforts to improve access, counseling and treatment for uninsured or underinsured men diagnosed with prostate cancer. UCLA Newsroom >
Aug 09, 2018
Dr. Christopher Saigal -- The Patient-Centered Outcomes Research Institute awarded $1.9 million to Dr. Christopher Saigal, UCLA Urology and Institute of Urologic Oncology faculty member, to fund research on ways to improve the decision-making process for men diagnosed with prostate cancer. UCLA Health News Release >
Jul 20, 2018
Dr. Amar Kishan -- Aggressive therapy for advanced prostate cancer helps men live longer
Renal & Urology News published an article on a recent study led by Dr. Amar Kishan, assistant professor in radiation oncology and member of the UCLA Jonsson Comprehensive Cancer Center, that found that men diagnosed with Gleason 10 prostate cancer had a high five-year overall survival rate, regardless of the type of aggressive treatment used.
May 16, 2018
Dr. Arie Belldegrun -- Ernst & Young LLP (EY) today announced that Arie Belldegrun, MD, FACS, visionary surgeon, scientist and life sciences entrepreneur, will be honored with the prestigious Master Entrepreneur Award during the Entrepreneur Of The Year 2018 Greater Los Angeles Awards gala on Thursday, June 14, at The Beverly Hilton Hotel.
May 4, 2018
Dr. Nicholas Nickols -- Dr. Nicholas Nickols, an assistant professor of radiation oncology, was quoted in a Reuters Health story about prostate cancer advances.
Apr 23, 2018
Dr. Andrew Goldstein -- Dr. Andrew Goldstein, Assistant Professor-in-Residence of Urology and Molecular, Cell & Developmental Biology, has been named a 2018 GIANTS OF SCIENCE Hope Award recipient by American Cancer Society for his early-career accomplishments. Dr. Goldstein is a laboratory scientist who works at the interface of cell biology and prostate cancer. His research is funded by the American Cancer Society, a STOP Cancer Foundation career development award, the Margaret E. Early Medical Research Trust, and the DGSSOM Cancer Theme. His lab focuses on CD38 methylation in prostate cancer progenitor cells and its role in regulating extracellular NAD, particularly in the setting of castrate-resistance. He developed and teaches a well-subscribed and highly rated undergraduate course on metabolism and disease.
April 20, 2018
Dr. Amar Kishan -- Prostate Knowledge and Practice Update featured an article citing recent work published in JAMA by Dr. Amar U. Kishan, an assistant professor of radiation oncology. Kishan and his colleagues found that treating advanced prostate cancer patients with external beam radiotherapy plus brachytherapy is significantly associated with better outcomes.
Mar 12, 2018
Dr. Amar Kishan -- ABC News Radio Australia featured research published by Dr. Amar Kishan, an assistant professor of radiation oncology and a member of the UCLA Jonsson Comprehensive Cancer Center, and colleagues finding that treating advanced prostate cancer patients with external beam radiotherapy plus brachytherapy is significantly associated with better outcomes.
Mar 02, 2018
Dr. Amar Kishan -- The study, led by UCLA researcher Dr. Amar Kishan, shows that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.
News Release > JAMA article > HealioHemOnc Today >
Jan 30, 2018
Dr. Leonard S. Marks -- UCLA researchers Dr. Leonard Marks and Shyam Natarajan will lead a $3.1 million research project grant awarded by the National Institutes of Health to advance the adoption of a promising new technology to treat men with prostate cancer. Marks is a professor and deKernion Endowed Chair of urology at the David Geffen School of Medicine and a UCLA Jonsson Comprehensive Cancer Center member. Story on newswise.com >
Jan 30, 2018
Dr. Allan Pantuck -- Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma in the S-TRAC trial (ClinicalTrials.gov number, NCT00375674). A prospectively-designed exploratory analysis of tissue biomarkers was conducted to identify predictors of treatment benefit. Story on urotoday.com >
Dec 14, 2017
Dr. Pantuck -- We often think of cancer as a one-time event, but recurrence after treatment is common in many cancers and patients often face limited clinical options. Approximately 300,000 people worldwide are diagnosed with renal cell carcinoma each year, and of the 16 percent of patients diagnosed with stage III or localized type of the disease, almost half will relapse following surgery and develop metastases. Sunitinib (marketed as Sutent) a drug that has already proven highly effective as first-line treatment for people with metastatic renal cell carcinoma, was recently approved by the U.S. Food and Drug Administration to also treat patients with the disease who are at high risk for tumor recurrence. View Article (PDF) >
Nov 06, 2017
Dr. Alexandra Drakaki -- MedPage Today featured a study led by Dr. Alexandra Drakaki, assistant professor of medicine in the division of hematology and oncology at the David Geffen School of Medicine at UCLA, about a vaccine against metastatic renal cell carcinoma that showed stability and safety in a phase 1 clinical trial. Drakaki is also a member of the UCLA Jonsson Comprehensive Cancer Center.
Sep 10, 2017
Dr. Nicholas Nickols -- Nicholas G. Nickols, MD, PhD, Awarded Grant to Identify Drivers of Prostate Cancer Metastasis. Nicholas G. Nickols, MD, PhD, an attending physician at the West Los Angeles Veteran Affairs Medical Center and Assistant Professor of Radiation Oncology at the David Geffen School of Medicine, has been awarded the prestigious 2017 VALOR Young Investigator Award by the Prostate Cancer Foundation. The grant will advance his research in identifying the biologic mechanisms that drive the spread of incurable prostate cancer in men with the disease. Dr. Nickols is conducting a trial combining surgery, stereotactic radiotherapy, and enhanced hormonal therapy in men with oligometastatic prostate cancer. He and his team will use genomic profiling to identify the specific biologic features that promote metastasis. The $225,000 grant will provide support for an office or lab space, equipment, staff, and 3 years of research support.
Aug 03, 2017
Dr. Christopher Saigal -- Software helps prostate cancer patients decide on treatment. Recent research in the Journal of Clinical Oncology shows that as many as 15 percent of prostate cancer patients later regret their treatment choice. Such difficulties led Dr. Christopher Saigal, vice chair of urology at UCLA, to develop a tool to simplify the choices for men and reduce what he calls “decisional conflict,” when patients experience stress about which treatment — and consequent risks — to choose. Story on newsroom.ucla.edu > Additional Coverage: Medical Xpress | MyScience.org
Jul 23, 2017
Dr. Pantuck -- Approximately 300,000 people worldwide are diagnosed with renal cell carcinoma each year, and of the 16 percent of patients diagnosed with stage III or localized type of the disease, almost half will relapse following surgery and develop metastases. A new study published in the New England Journal of Medicine has shown for the first time that use of the cancer drug sunitinib in an adjuvant setting can significantly improve disease-free survival in patients who are at high risk for tumor recurrence. View Article (PDF) >
Jul 07, 2017
Dr. Belldegrun -- Since joining UCLA’s faculty in 1988, urology researcher Arie Belldegrun has developed a specialty: starting companies with the university’s help. Belldegrun’s track record includes selling his first company, the Santa Monica cancer therapy biotech Agensys Inc., for more than $500 million. In 2009, Belldegrun’s Cougar Biotechnology was sold to Johnson & Johnson, for $1 billion. He’s still running the cancer cell therapy firm, Kite Pharma, which recently ranked seventh in the MIT Technology Review’s 2017 list of the 50 smartest companies. View on latimes.com >
Jul 03, 2017
Dr. Mark Litwin -- Prostate cancer diagnosis and treatment have evolved. Here’s where we are:
Dr. Mark Litwin, Chair of UCLA Urology, has just published a review of the diagnosis and treatment of prostate cancer in JAMA.
View Prostate Cancer Blog Post >.
Dec 08, 2016
Dr. Andrew Goldstein -- Technology.org, Medical News Today, MedicalXpress, and News-Medical.Net reported Dec. 7, and Bio Portfolio, Science Daily and Dolphnsix News reported Dec. 6 on a study finding that the progenitor cells located in unusually high numbers in inflamed areas of the prostate can increase the risk for cancer. Dr. Andrew Goldstein, assistant professor of urology at the David Geffen School of Medicine at UCLA was lead author of the study and was quoted. Goldstein is also a member of UCLA’s Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine & Stem Cell Research.
Story on technology.org > Additional Coverage: uclahealth.org > | Urology Times >
Oct 04, 2016
Dr. Christopher Saigal -- Dr. Christopher Saigal, professor and vice chair of the UCLA Department of Urology and member of UCLA’s Jonsson Comprehensive Cancer Center, was featured Oct. 4 in a KNX-AM report on the controversy surrounding the prostate-specific antigen (PSA) test following reports that actor Ben Stiller underwent the test and was diagnosed with prostate cancer.
Story on KNX-AM >
Nov 17, 2016
Dr. Pantuck -- The UCLA Department of Urology is honored to announce that Dr. Allan Pantuck, Professor of Urology, has been appointed as the new Chair of the UCLA Medical Institutional Review Board (IRB).
View Announcement >
Jun 13, 2016
Dr. Leonard S. Marks -- A pioneering therapy using high powered laser beams may cure prostate cancer, according to research. The sci-fi style technology doesn't require surgery and has already been successful in zapping the tumours of 19 men. It 'fuses' an MRI (magnetic resonance imaging) scanner with ultrasound to identify diseased cells. A precisely targeted laser fibre is then heated up to annihilate them. Urologist Professor Leonard Marks, of the University of California, Los Angeles, said: 'Our feeling was if you can see prostate cancer using the fusion MRI and can put a needle in the spot to biopsy it, why not stick a laser fibre in the tumour the same way to kill it.
Story on dailymail.co.uk >
Jun 10, 2016
Dr. Leonard S. Marks -- Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation - the precise application of heat via laser to a tumor - is both feasible and safe in men with intermediate risk prostate cancer.
Story on eurekalert.org >
Aug 05, 2016
Dr. Amar Kishan -- A study by researchers at the UCLA Jonsson Comprehensive Cancer Center provides convincing evidence that radiation-based treatments and surgery are equally effective treatments for aggressive prostate cancer.
Story on uclahealth.org >
Jul 13, 2016
Dr. Karim Chamie -- UCLA researchers have identified the incidence and long-term outcomes of patients who develop second, unrelated cancers, resulting in a data set that they say sheds new light on the way cancer survivors may need to be monitored post-disease.
Story on newsroom.ucla.edu >
Sep, 30, 2015
Dr. Fairooz Kabbinavar -- A new collaboration between UCLA and the VA Greater Los Angeles Healthcare System will provide access to the latest therapeutic cancer clinical trials and state-of-the-art care for men and women who have served in the armed forces.
Story on uclahealth.org >
Oct 30, 2014
Campus officials dedicated the Edie & Lew Wasserman Building, a new landmark research and patient-care facility at UCLA, at a festive ceremony on Tuesday, Oct. 28.
Story on newsroom.ucla.edu >
PubMed Publications by IUO Faculty:
William Aronson, MD
Arie Belldegrun, MD
Karim Chamie, MD, MSHS
Arnold I-Dah Chin, MD, PhD
Jean B. DeKernion, MD
Alexandra Drakaki, MD
Ely Felker, MD
Isla Garraway, MD
Christopher King, MD, PhD
Patrick Kupelian, MD
Mark S. Litwin, MD, MPH
Leonard S. Marks, MD
Allan Pantuck, MD, MS, FACS
Steven Raman, MD
Jian Yu Rao, MD
Nagesh P. Rao, PhD, FACMG
Robert E. Reiter, MD
Matthew Rettig, MD
Jonathan Said, MD
Christopher Saigal, MD, MPH
Anthony E. Sisk, Jr., DO
Robert B. Smith, MD
Lily Wu, MD, PhD
Gang Zeng, PhD
Nazy Zomorodian, RNC, MSN, CUNP